A5018352586- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Advanced Breast Cancer Therapies
- Head and Neck Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer-related molecular mechanisms research
- Renal cell carcinoma treatment
- Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Lung Cancer Research Studies
- Tumors and Oncological Cases
- MicroRNA in disease regulation
- PI3K/AKT/mTOR signaling in cancer
- Circular RNAs in diseases
- Cancer Mechanisms and Therapy
- Mathematical Biology Tumor Growth
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
- Genomic variations and chromosomal abnormalities
- Nonmelanoma Skin Cancer Studies
Tokyo Medical and Dental University
2017-2025
Tokyo Medical and Dental University Hospital
2017-2025
Yokohama City University Hospital
2025
Yokohama City University
2025
Yokohama City University Medical Center
2025
The University of Tokyo
2022-2024
The Cancer Institute Hospital
2024
Kameda Medical Center
2024
University of California, San Diego
2015-2023
Chugai Pharma (United States)
2020
MicroRNAs are recently discovered regulators of gene expression and becoming increasingly recognized as important heart function. Genome-wide profiling microRNAs in human failure has not been reported previously. We measured 428 67 left ventricular samples belonging to control (n = 10), ischemic cardiomyopathy (ICM, n 19), dilated (DCM, 25), or aortic stenosis (AS, 13) diagnostic groups. miRNA between disease groups was compared by ANOVA with Dunnett's post hoc test. controlled for multiple...
Calcium signaling is a central regulator of cardiomyocyte growth and function. Calmodulin critical mediator calcium signals. Because the amount calmodulin within cardiomyocytes limiting, precise control expression important for regulation signaling. In this study, we show first time that levels are regulated posttranscriptionally in heart failure. The cardiomyocyte-restricted microRNA miR-1 inhibited translation calmodulin-encoding mRNAs via highly conserved target sites their 3′...
Molecular aberrations in the phosphatidylinositol-3-kinase (PI3K) pathway drive tumorigenesis. Frequently co-occurring alterations hormone receptors and/or human epidermal growth factor receptor 2 (HER2) may be relevant to mechanisms of response and resistance.To identify patterns aberration PI3K interactive pathways that might lead targeted therapy opportunities clinical practice.From January 2013 through December 2014, 19 784 consecutive tumor samples (>40 cancer types) were sent from...
An important event in the pathogenesis of heart failure is development pathological cardiac hypertrophy. In cultured cardiomyocytes, transcription factor Gata4 required for agonist-induced We hypothesized that, intact organism, an regulator postnatal function and hypertrophic response to stress. To test this hypothesis, we studied mice heterozygous deletion second exon ( G4D ). At baseline, had mild systolic diastolic dysfunction associated with reduced weight decreased cardiomyocyte number....
Alternative mRNA splicing is an important mechanism for regulation of gene expression. Altered occurs in association with several types cancer, and a small number disease-associated changes have been reported heart disease. However, genome-wide approaches not used to study We hypothesized that different diseased hearts compared control hearts.
Abstract Metastatic basal cell carcinomas are rare malignancies harbouring Hedgehog pathway alterations targetable by SMO antagonists (vismodegib/sonidegib). We describe, for the first time, molecular genetics and response of a patient with inhibitor-resistant metastatic carcinoma who achieved rapid tumour regression (ongoing near complete remission at 4 months) nivolumab (anti-PD1 antibody). He had multiple hallmarks anti-PD1 responsiveness including high mutational burden (>50 mutations...
Abstract Noninvasive genomic profiling of tumors may be possible with next-generation sequencing (NGS) blood-derived circulating tumor DNA (ctDNA), but proof concept in a large cohort patients diverse cancers has yet to reported. Here we report the results an analysis plasma-derived ctDNA from 670 cancers. The represented patient were mainly gastrointestinal (31.8%), brain (22.7%), or lung (20.7%). obtained most [N = 423 (63%)] displayed at least one alteration. frequent alterations seen, as...
Abstract Background To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, Clinical and Cancer Association, jointly published “Clinical practice guidance for next-generation sequencing cancer diagnosis treatment” 2017. Since new information on genomic medicine has emerged since 1st edition was released, including reimbursement NGS-based multiplex gene panel tests 2019, revision made. Methods A working group organized with 33 researchers from designated...
IMPORTANCE Precision oncology using comprehensive genomic profiling (CGP) by next-generation sequencing is aimed at companion diagnosis and profiling. The clinical utility of CGP before the standard care (SOC) still not resolved, more evidence needed. OBJECTIVE To investigate (FoundationOne CDx [F1CDx]) in patients with previously untreated metastatic or recurrent solid tumors. DESIGN, Setting, Participants This multicenter, prospective, observational cohort study enrolled advanced tumors...
Because imaging has a high sensitivity to diagnose hepatocellular carcinoma (HCC) and tissue biopsies carry risks such as bleeding, the latter are often not performed in HCC. Blood-derived circulating tumor DNA (ctDNA) analysis can identify somatic alterations, but its utility been characterized HCC.We evaluated 14 patients with advanced HCC (digital ctDNA sequencing [68 genes]). Mutant relative wild-type allele fraction was calculated.All (100%) had alterations (median = 3...
Abstract Purpose: Molecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical hepatocellular carcinoma (HCC) given the challenge of obtaining liver tissue biopsies. Experimental Design: We analyzed blood samples from 206 with HCC using comprehensive genomic testing (Guardant Health) circulating tumor DNA (ctDNA). Results: A total 153/206 (74.3%) were men; median age, 62 years (range, 18–91 years). 181/206 had ≥1...
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in pan-cancer setting order to understand immune landscape metastatic malignancies as well anti-PD-1/PD-L1 inhibitor resistance mechanisms. Interrogation 51 markers cancer-immunity cycle was performed 101 diverse using a clinical-grade RNA sequencing assay. Overall, phenotypes...
Introduction Clinical sequencing has provided molecular and therapeutic insights into the field of clinical oncology. However, despite its significance, utility in Japanese patients remains unknown. Here, we examined tissue-based with FoundationOne ® CDx Heme. Between August 2018 2019, 130 pretreated advanced solid tumors were tested or Results The median age was 60.5 years (range: 3 to 84 years), among them, 64 males 66 females. Major cancer types gastrointestinal (23 cases) hepatic,...
Comprehensive cancer genome profiling (CGP) has been nationally reimbursed in Japan since June 2019. Less than 10% of the patients have reported to undergo recommended treatment. Todai OncoPanel (TOP) is a dual DNA-RNA panel as well paired tumor-normal matched test. Two hundred underwent TOP part Advanced Medical Care B with approval from Ministry Health, Labour and Welfare between September 2018 December Tests were carried out cancers without standard treatment or when had already undergone...
Hepatocellular carcinoma (HCC) has limited treatment options. Molecular analysis of its mutational landscape may enable the identification novel therapies. However, biopsy is not routinely performed in HCC. The utility analyzing cell-free circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) established. We 32 ctDNA NGS analyses on 26 patients; 10 these patients had tissue (236 to 626 genes). was evaluated using an assay that detects single nucleotide variants, amplifications,...
Abstract Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug clinically approved for patients with advanced HCC, blocks Ras/Raf/MAPK pathway but it does not inhibit PI3K/AKT/mTOR or activation. Hence, there is an unmet medical need to identify potent PI3K/BRD4 inhibitors, which can be used either alone combination sorafenib treat HCC. Herein, we show that SF1126 (pan inhibitor) as...
SMARCA4-deficient thoracic sarcoma is a rare tumor typically presenting as mediastinal mass. The prognosis estimated to be poor, and no effective treatment has been established. We present case of 76-year-old man who was diagnosed with sarcoma. provisional diagnosis carcinoma unknown primary but subsequently corrected based on the panel-based cancer gene screening immunohistochemistry. Cytotoxic chemotherapy first- second-line did not reveal enough therapeutic effects third-line therapy...
Antiangiogenesis therapy has become a vital part of the armamentarium against cancer. Hypertension is dose-limiting toxicity for VEGF inhibitors. Thus, there pressing need to address associated adverse events so these agents can be better used. The hypertension may mediated by reduced NO bioavailability resulting from inhibition. We proposed that prevented coadministration with endostatin (ES), an endogenous angiogenesis inhibitor antitumor effects shown increase endothelial production in...
We analyzed clinical associations of MET alterations in the plasma patients with diverse malignancies. Digital sequencing circulating tumor DNA (ctDNA) (54–70 genes) was performed 438 patients; 263 also had tissue (182–315 genes). The most represented types were gastrointestinal (28.1%), brain (24.9%), and lung (23.2%). Most (71.2%) recurrent/metastatic disease. observed 31 (7.1%) correlated bone metastasis (P = 0.007), TP53 0.001) PTEN 0.003) abnormalities, an increased number (median, 4 vs...